Morgan Stanley has initiated coverage of Attovia Therapeutics with an Overweight rating and a price target of $39, citing the company's blockbuster potential. UBS upgraded Kaiser Aluminum to Buy from Neutral, setting a price target of $184, noting that shares are currently about 19% below their August highs due to factors like USMCA renegotiations and a CEO transition.
Roth initiated coverage of Ticketplus as a Buy, emphasizing its leadership in the Latin American live events technology market. Baird upgraded Deere to Outperform, predicting strong demand for North American agricultural equipment.
Jefferies reiterated its Underperform rating on Apple, citing potential downside risks for iPhone volumes and gross margins in the upcoming quarters, while noting that price hikes in China may be less than previously forecasted. Evercore ISI initiated coverage of Lumentum with an Outperform rating and a $1,100 target, indicating confidence in the company's growth prospects.
Bernstein remains optimistic about SpaceX, despite uncertainties in its direct-to-device mobile business. Melius reiterated its Buy rating on Nvidia, suggesting the stock may soon break out despite market concerns. Evercore ISI also initiated coverage of Redcat with an Outperform rating and a $15 price target, highlighting its strong position in the drone manufacturing sector.
Needham initiated coverage of Babcock & Wilcox Enterprises with a Buy rating, citing a repaired balance sheet. Goldman Sachs initiated Braveheart Bio as a Buy with a $48 price target, while Bank of America raised its price target for Dell to $505 ahead of earnings, emphasizing confidence in future earnings growth.
Compass Point upgraded MidCap Financial Investment to Buy, and KBW initiated River City Bank as Outperform, describing it as a strong player in commercial real estate lending. JPMorgan reiterated its Overweight ratings on Broadcom, Nvidia, and Marvell, viewing them as key beneficiaries of the AI infrastructure buildout.
Gordon Haskett maintained its Buy rating on Costco, noting the company's resilience amid macroeconomic uncertainties. Lastly, Argus upgraded Abercrombie & Fitch to Buy, citing improved sales momentum in recent quarters